<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 55-year-old woman suffered from a bloodstream <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (Staphylococcus aureus), which originated from pump inflow and outflow skin exits, from 4 months after a parocorporeal left ventricular assist device (LVAD) had been implanted </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to local irrigation, repeated administration of a weekly unit of <z:chebi fb="0" ids="474053">cefazolin</z:chebi> <z:chebi fb="1" ids="35505">hydrate</z:chebi> was temporarily effective, but <z:hpo ids='HP_0001945'>fever</z:hpo> frequently recurred </plain></SENT>
<SENT sid="2" pm="."><plain>Because short-term antibiotic administration had limited effectiveness, a much longer-term course of <z:chebi fb="0" ids="474053">cefazolin</z:chebi> was begun at 14 months post-LVAD implantation and was planned to continue until future transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>Unfortunately, the patient died from a <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> at 19 months after LVAD implantation; long-term consecutive <z:chebi fb="0" ids="474053">cefazolin</z:chebi> administration had suppressed the <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> for over 5 months without side effects </plain></SENT>
<SENT sid="4" pm="."><plain>To treat intractable LVAD-associated bloodstream <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, long-term administration of a narrow-spectrum <z:chebi fb="0" ids="35627">beta-lactam</z:chebi> drug is an effective option </plain></SENT>
</text></document>